Methamphetamine-Associated Psychosis (MAP) – The Clinical Spectrum

Posted on:January 13, 2019
Last Updated: December 22, 2021
Time to read: 7 minutes

Recent years have seen a dramatic increase in the use of the synthetic stimulant, methamphetamine, particularly in its crystalline form.

Advances in methamphetamine processing have resulted in a drug that now has a higher average purity (increased from 21% to 64%) and therefore a higher potency.

This increase in purity and potency has resulted in an increased price ($464 to $795 per gram) however the average purity-adjusted price per gram has declined. [1]

Taken together, these increases in purity and potency as well as its favourable pricing, is challenging people’s control of methamphetamine consumption.

This, in turn, has resulted in the rise in methamphetamine-related harm. From a clinical perspective, there is consistent evidence that methamphetamine use is associated with: [2], [3]

  • Clinical features including delusions and cognitive impairment
  • Increased psychological distress and higher rates of depression and anxiety
  • Methamphetamine-associated psychosis (MAP) resulting from chronic use

We covered the assessment and management of methamphetamine addiction in a previous article. This article focuses on the methamphetamine associated psychotic symptoms and the differences from a primary psychotic illness.